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T
rained in research by some of the 
giants of immunology, Laurie 
Glimcher is herself a major force 
in that fi  eld. Most of her career has fo-
cused on understanding how different 
subsets of immune cells develop and are 
regulated (1). However, Glimcher is 
known in cell biology circles for her 
discovery of XBP-1 (2), a transcription 
factor that turned out to be important in 
lipogenesis (3) and in the ER stress or un-
folded protein response (UPR).
Determined to follow an interesting 
lead wherever it will take her, Glimcher 
devotes part of her time toward under-
standing the interplay of ER stress with 
immune function and neurodegenera-
tion (4, 5). Meanwhile, she continues to 
explore the regulation of immune func-
tion, while also making waves in the 
field of osteobiology (6). We spoke 
with her about how she’s driven her ca-
reer across professional and disciplin-
ary boundaries.
QUEST FOR KNOWLEDGE
As an MD, what made you want to 
pursue research on top of being a 
doctor?
It was the quest for knowledge, and the 
questions that went with it that drew me 
in. I became fascinated by immunology 
when I was a first-year 
medical student at Har-
vard. I was curious about 
how the immune system 
is regulated and why it is 
dysregulated in autoim-
mune diseases—when 
the cells of your immune 
system start attacking your 
own body. In my fourth 
year of medical school I 
spent basically all of my elective time—
about nine months—in Harvey Cantor’s 
lab. While I was there, we identified a 
protein that would later become known 
as Nk1.1, which ended up being pretty 
valuable in immunology circles, and 
for which I received the Soma Weiss 
Award. That was particularly meaning-
ful to me because my father, who had 
done his own medical training and 
spent all of his career at Harvard, had 
won that award 26 years earlier, and be-
cause I was the first woman to win it. I 
guess you could call that a turning point 
for me.
You didn’t abandon medicine for 
research right away, though?
No. I fi  nished one year of internship and 
one year of residency because my hus-
band, whom I met at medical school, 
was doing three years of residency at 
Harvard. By the time I was in my sec-
ond year of residency, I was already 
casting around for research projects to 
do. It wasn’t that I was bored, it was just 
that being a physician was not for me an 
intellectually creative endeavor. What 
always fascinated me was not so much 
treating patients with disease, but fi  gur-
ing out why they had the disease. That 
was really what I cared about. So, I 
sought and received a position at the 
NIH, where I continued my research in 
immunology with Bill Paul.
The three years I spent at NIH were 
wonderful. The atmosphere was so vi-
brant and the immunolo-
gy fi   eld was really bus-
tling. I got great training 
from Bill, who was a 
wonderful mentor to me, 
and who encouraged me 
to pursue research on my 
own afterwards. I wrote 
and was awarded my own 
RO1 grant before my hus-
band and I returned to 
Harvard so we could both fi  nish  our 
medical training. I’d had four and a half 
years of postdoc—call it what you 
will—before I started my own lab back 
at Harvard.
JUGGLING ACT
You were starting up your own lab and 
doing your residency simultaneously?
You know, it was tough. I had my grant, 
and momentum from the work I’d started 
with Bill Paul. I had a hood and a small 
bench, but I didn’t really have any men-
torship or anything. There was nobody to 
provide me with intellectual, emotional, 
or fi  nancial support. Certainly for that 
fi  rst year and a half when I was simulta-
neously trying to do my research and be 
a rheumatology fellow, there were very 
few immunologists at MGH (Massachu-
setts General Hospital) that I could speak 
to, so I was really fl  ying by the seat of 
my pants.
I’ve tried hard to not have that happen 
to the people I train. I want to make their 
transition from postdoc to faculty a much 
more mentored and supported road. I was 
able to do it on my own, but it was hard. I 
was trying to juggle residency and re-
search and, by that time, two children! 
My husband was a surgery resident, and 
they are kept fantastically busy, so for a 
while we almost never saw each other.
How did you manage the competing 
demands of family and work?
I think I did it by becoming very well organ-
ized. I’m not smarter than anybody else; 
Glimcher pursues a cross-disciplinary understanding of how cell 
biology affects the immune system.
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I’m just exceptionally effi  cient. If I wrote 
out a list of things that I had to do, they 
would all get done that day. The other 
thing I learned to do was to prioritize. I 
had to give up the idea of being a perfec-
tionist with anything but the data. When 
writing reviews or grants or whatever, 
once you get it to a good stage, you have 
to call it done and let it go. You have to 
be willing to compromise on those 
things, and also about things being per-
fect at home. Does anybody care if the 
sheets are folded exactly right?
But I don’t think you should ever have 
to choose between having kids and hav-
ing a career. I always wanted to have 
kids, so I was going to make it work, and 
I am so glad I did, though I’d never have 
been able to manage it if my parents 
hadn’t been around to help. Many peo-
ple, women especially, struggle with this. 
I don’t think it’s fair, so I do whatever I 
can to support them. In my lab I make 
sure they have the support of a techni-
cian so they can get the most out of their 
training while still having a family, if 
they should so choose.
TAKE ALL ROADS
Do you have any other advice for young 
scientists?
Be a risk taker and don’t be afraid to try 
new things. I have gone from one area 
of research to the next over the last 25 
years, driven by the discoveries we’ve 
made, and with every shift I’ve had to 
learn a new field. You have to be will-
ing to ask the experts for their help. Do 
lots of reading. Go to meetings. Make 
the leap.
For example, since the late 1980s my 
lab has been studying this transcription 
factor, XBP-1. We cloned XBP-1 because 
we’d been studying the regulation of 
MHC class II, a protein family central 
to immune surveillance. We’d identifi  ed 
a region, called the X-box, in the gene 
sequence of one MHC class II family 
member, which when mutated disrupted 
gene transcription. I remember I was in 
the hospital after having my third child 
when my graduate student brought me 
the fi  lm of a Southwestern blot she’d 
done to pull out a protein that bound the 
X-box sequence. That 
protein turned out to be 
XBP-1, so we went 
ahead and made XBP-1 
knockout mice, fully ex-
pecting that they would 
have impaired MHC 
class II production. But 
lo and behold, when we 
fi  nally got a mouse, the 
gene had nothing to do 
with MHC class II. We 
found it was involved in 
lipogenesis, and other 
groups later showed it to 
be a linchpin of the un-
folded protein, or ER stress response—
if you delete XBP-1, you activate the 
ER stress response. In fact, XBP-1 and 
ER stress turned out to regulate a com-
pletely different branch of the immune 
system: the differentiation of plasma 
cells, which are the cells that make pro-
tective antibodies.
This work has spurred other kinds of 
questions, like whether XBP-1 functions 
in autoimmune diseases. When we deleted 
XBP-1 from gut epithelial cells, we found 
that it activated a pro-infl  ammatory re-
sponse in the cells.
Over time, XBP-1 has led us in lots 
of different directions, so my students 
and I have had to get acquainted with 
these new fields. I’ve never felt myself 
to be an expert in any of them, even in 
immunology. I think some may accuse 
me of being a dilettante. But I wouldn’t 
do anything differently because it’s so 
much fun. You have the opportunity to 
make really new discoveries that are 
important in a new fi  eld. I love that. I 
don’t want to just refine and extend 
what I’ve already been doing. The most 
exciting thing to me is to come up with 
a new idea, no matter what field it’s in, 
and have it actually prove to be true.
What new directions are you headed 
in now?
My research interests are becoming in-
creasingly cross-disciplinary. It can be 
really liberating to enter a new area, be-
cause you come into it 
without any prejudices, 
and you’re able to take a 
fresh perspective. We’re 
looking now at how the 
systems we’ve been 
studying in my lab all 
this time interrelate. For 
example, how does the 
immune system and the 
ER stress system in neu-
rons impact neurodegen-
erative diseases? Recent-
ly I’ve also gotten inter-
ested in skeletal biology, 
which in some ways is 
simpler than immunobiology since 
there are fewer cell types to worry 
about. Now probably half my lab is 
working in osteobiology. This work was 
instigated by our discovery of an adapt-
er protein called Schnurri-3 that con-
trols adult bone mass, coauthored with 
my father, a bona fide skeletal biolo-
gist. But who knows where we’ll go in 
the future?
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Glimcher and her father collaborated on 
recent research.
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